Provectus Biopharmaceuticals, Inc.
PVCT
$0.0749
-$0.0042-5.31%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -5.40M | -4.76M | -3.03M | -2.79M | -2.78M |
| Total Depreciation and Amortization | 5.40K | 7.10K | 8.80K | 8.80K | 8.80K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.62M | 1.33M | 46.80K | 49.10K | 48.50K |
| Change in Net Operating Assets | 437.50K | 142.80K | 39.70K | -405.00K | -271.50K |
| Cash from Operations | -3.33M | -3.28M | -2.93M | -3.14M | -2.99M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 2.34M | 2.85M | 2.55M | 2.79M | 2.84M |
| Total Debt Repaid | -300.10K | -405.10K | -391.90K | -398.40K | -386.00K |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 1.00M | 300.00K | -- | -- | -- |
| Cash from Financing | 3.04M | 2.75M | 2.16M | 2.39M | 2.46M |
| Foreign Exchange rate Adjustments | -100.00 | -800.00 | -23.60K | -22.00K | -23.20K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -293.40K | -537.10K | -796.00K | -769.90K | -558.70K |